Astrazeneca Pharma India Ltd

• 

  AstraZeneca Pharma's Cancer-Treating Drug Gets Regulator's Nod In India

  AstraZeneca Pharma India Ltd on Wednesday said it has received an approval from the Drug Controller General of India (DCGI) for the cancer drug trastuzumab deruxtecan for treatment of metastatic breast cancer.

• 

  AstraZeneca, Dr Reddy's Ink Diabetes Drug Distribution Pact

  AstraZeneca Pharma India and Dr Reddy's Laboratories on Friday entered into a distribution agreement for two drugs - Riax and Riax-M - used for treatment of diabetes in India.

• 

  AstraZeneca Pharma Q4 Profit at Rs 38 Cr

  AstraZeneca Pharma India on Wednesday reported a net profit of Rs 38.12 crore for the fiscal fourth quarter that ended on March 31, 2015.

• Promoter-Banker-Foreign Fund Nexus Under Scanner Over Participatory Notes: Report

  Suspecting illicit insider trading and market manipulation through misuse of the 'participatory note' route, the Securities and Exchange Board of India (Sebi) is probing a possible nexus between promoters of listed companies, investment bankers and foreign funds for such activities.

• 

  Astrazeneca Pharma India Falls; SEBI Says Exchanges to Monitor Delisting

  The regulator also said it came across certain reports that the offer for sale (OFS) of the shares of Astrazeneca Pharma India Ltd carried out by its promoter AstraZeneca Pharmaceuticals AB Sweden on May 26, 2013 was a deliberate attempt to subsequently get the shares of the Indian unit delisted at ease.

• AstraZeneca India unit sets floor price for stock delisting

  AstraZeneca Pharma India's stock has risen nearly 50 percent from the year's low on January 30 to touch Rs 1,092.35 on Friday on delisting expectations, while the Mumbai market rose roughly 12 percent in that period.

• Big Pharma pushes for US action against India over patent worries: report

  Global pharmaceutical firms are pressuring the United States to act against India to stop more local companies producing up to a dozen new varieties of cheap generic drugs still on-patent, sources with direct knowledge of the matter said.

• AstraZeneca Pharma promoter to sell stake in Indian arm

  AstraZeneca Pharma India said on Friday that its promoter AstraZeneca Pharmaceuticals AB Sweden plans to offload around 37 lakh shares through offer for sale route on May 28 to meet the Securities and Exchange Board of India (Sebi) norms on minimum public shareholding.

• Companies to seek extension of June deadline, easing norms from Sebi

  With less than two months left for lowering their promoter holding to 75 per cent, many private sector companies are planning to petition Sebi to relax the norms -- either by way of a deadline extension or relaxation in the compliance procedures.

• AstraZeneca Pharma India Ltd - Resignation of Director

  AstraZeneca Pharma India Ltd has informed BSE that Mr. Francis Vincent Mcnamara III has resigned as a Director of the Company with effect from September 30, 2010.

• AstraZeneca Pharma India Ltd - Updates on Result of Postal Ballot

  AstraZeneca Pharma India Ltd has informed BSE that regarding "Voting details on the Special Resolution through Postal Ballot for Seeking consent of the Shareholders to the Delisting of Equity Shares of the Company".